Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.

Full Abstract

BACKGROUND: Aromatase inhibitors may affect lipid metabolism, inflammatory response and antioxidant balance. PATIENTS AND METHODS: One hundred and eighty-six post-menopausal patients with breast carcinoma underwent evaluation of parameters of lipid metabolism, inflammatory response and antioxidant balance immediately before as well as 2 and 4 months after the start of therapy with aromatase inhibitors. RESULTS: A significant increase in total, very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol, lipoprotein (a), retinol, C-reactive protein and fibrinogen was observed. The changes of serum lipid concentrations were restricted mostly to the patients pre-treated with tamoxifen who had significantly lower baseline levels of these parameters. CONCLUSION: An increase of serum cholesterol, lipoprotein (a), C-reactive protein and fibrinogen in patients treated with aromatase inhibitors is the result of tamoxifen withdrawal rather than a direct effect of therapy. No significant changes in serum lipids were observed in patients treated with aromatase inhibitors in the first-line setting.

Author information

Author/s: Melichar, Bohuslav (B); Kalábová, Hana (H); Krcmová, Lenka (L); Urbánek, Lubor (L); Hyspler, Radomír (R); Solichová, Dagmar (D); Melicharová, Karolina (K); Pecka, Miroslav (M); Zadák, Zdenek (Z);

Affiliation: Department of Oncology, Palacký University Medical School & Teaching Hospital, I.P. Pavlova 6, 77520 Olomouc, Czech Republic. bohuslav.melichar(-atsign-)fnol.cz

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Anticancer research (Anticancer Res), published in Greece. (Language: eng)

Reference: 2009-Aug; vol 29 (issue 8) : pp 3337-46

Dates: Created 2009/08/07; Completed 2009/09/30;

PMID: 19661353, status: MEDLINE (last retrieval date: 9/30/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antineoplastic Agents, Hormonal - pharmacology
Aromatase Inhibitors - pharmacology
Breast Neoplasms - drug therapy; metabolism; pathology
C-Reactive Protein - metabolism
Fibrinogen - metabolism
Humans
Lipoprotein(a) - metabolism
Lipoproteins, LDL - metabolism

Associated Chemicals: Antineoplastic Agents, Hormonal (0) ; Aromatase Inhibitors (0) ; Lipoprotein(a) (0) ; Lipoproteins, LDL (0) ; Lipoproteins, VLDL (0) ; Tamoxifen (10540-29-1) ; Vitamin A (11103-57-4) ; alpha-Tocopherol (59-02-9) ; Neopterin (670-65-5) ; Fibrinogen (9001-32-5) ; C-Reactive Protein (9007-41-4)

These are the highest related articles currently in the database: